Morgan Stanley Syndax Pharmaceuticals Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Morgan Stanley holds 849,236 shares of SNDX stock, worth $13.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

849,236

Previous 2,281,916 62.78%

Holding current value

$13.7 Million

Previous $28 Million 71.63%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$8.9 - $14.15 $12.8 Million - $20.3 Million	-1,432,680 Reduced 62.78%	849,236 $7.96 Million
Q1 2025 May 15, 2025	SELL	$12.29 - $16.38 $37.2 Million - $49.6 Million	-3,030,906 Reduced 57.05%	2,281,916 $28 Million
Q4 2024 Feb 14, 2025	BUY	$12.52 - $21.81 $55.4 Million - $96.5 Million	4,425,677 Added 498.87%	5,312,822 $70.2 Million
Q3 2024 May 14, 2025	BUY	$17.93 - $24.81 $2.35 Million - $3.25 Million	130,913 Added 17.31%	887,145 $17.1 Million
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $2.35 Million - $3.25 Million	130,913 Added 17.31%	887,145 $17.1 Million
Q2 2024 May 14, 2025	SELL	$18.82 - $23.79 $85.8 Million - $108 Million	-4,556,590 Reduced 85.77%	756,232 $15.5 Million
Q2 2024 Oct 17, 2024	SELL	$18.82 - $23.79 $19.9 Million - $25.2 Million	-1,059,526 Reduced 58.35%	756,232 $15.5 Million
Q2 2024 Aug 14, 2024	SELL	$18.82 - $23.79 $19.9 Million - $25.2 Million	-1,059,526 Reduced 58.35%	756,232 $15.5 Million
Q1 2024 Oct 17, 2024	BUY	$19.71 - $24.57 $20.9 Million - $26 Million	1,059,526 Added 140.11%	1,815,758 $43.2 Million
Q1 2024 Aug 16, 2024	BUY	$19.71 - $24.57 $2.99 Million - $3.72 Million	151,452 Added 9.1%	1,815,758 $43.2 Million
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $2.99 Million - $3.72 Million	151,452 Added 9.1%	1,815,758 $43.2 Million
Q4 2023 Aug 16, 2024	BUY	$11.39 - $21.67 $10.3 Million - $19.7 Million	908,074 Added 120.08%	1,664,306 $36 Million
Q4 2023 Feb 13, 2024	BUY	$11.39 - $21.67 $12.7 Million - $24.1 Million	1,114,277 Added 202.59%	1,664,306 $36 Million
Q3 2023 Nov 15, 2023	BUY	$14.52 - $21.77 $1.75 Million - $2.62 Million	120,309 Added 28.0%	550,029 $7.99 Million
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $12.9 Million - $14.8 Million	-664,124 Reduced 60.71%	429,720 $8.99 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $19.5 Million - $27.4 Million	944,475 Added 632.31%	1,093,844 $23.1 Million
Q4 2022 Feb 14, 2023	SELL	$20.64 - $26.24 $189,929 - $241,460	-9,202 Reduced 5.8%	149,369 $3.8 Million
Q3 2022 Nov 14, 2022	SELL	$18.51 - $24.79 $2.46 Million - $3.3 Million	-133,106 Reduced 45.63%	158,571 $3.81 Million
Q2 2022 Oct 27, 2022	SELL	$13.64 - $19.48 $5.54 Million - $7.91 Million	-406,024 Reduced 58.19%	291,677 $5.61 Million
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $5.54 Million - $7.91 Million	-406,024 Reduced 58.19%	291,677 $5.61 Million
Q1 2022 Oct 27, 2022	BUY	$14.84 - $22.15 $6.03 Million - $8.99 Million	406,024 Added 139.2%	697,701 $12.1 Million
Q1 2022 May 13, 2022	BUY	$14.84 - $22.15 $6.24 Million - $9.31 Million	420,225 Added 151.45%	697,701 $12.1 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $370,652 - $546,852	24,337 Added 9.61%	277,476 $6.07 Million
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $3.51 Million - $5.01 Million	253,139 New	253,139 $4.84 Million

Others Institutions Holding SNDX

# of Institutions

248

Shares Held

100M

Call Options Held

1.28M

Put Options Held

1.29M

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $916M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account